Are you a Stanford student interested in enrolling in MS&E 472: The Entrepreneurial Thought Leaders Seminar? Check out our course FAQ!

Where is AI-Driven Bioengineering Headed Next?

Russ Altman, Stanford University
and Kim Branson, GSK
In conversation with: Jack Fuchs, Stanford University

Stanford professor Russ Altman emphasizes that AI is opening new opportunities to understand how medicines interact with specific proteins, and build more highly customized therapies. He points to DeepMind’s AlphaFold 2 deep learning system as a particularly powerful new tool for re-envisioning how drugs are discovered and designed.